Methylphenidate Hydrochloride Tablet, Extended Release
Brand names: Concerta, Methylphenidate Hydrochloride, Relexxii
Category: Psychiatry
Unavailable 4Limited 11Available 19
FDA status: Current · Last FDA update: Sep 18, 2026 · First posted: Jul 26, 2023 (in shortage 3 years 2 months) · 6 manufacturers, 34 listed presentations
As of Sep 18, 2026, the FDA lists Methylphenidate Hydrochloride Tablet, Extended Release as currently in shortage. Of 34 manufacturer presentations, 4 Unavailable, 11 Limited, 19 Available.
Ask your pharmacist: which of the 6 manufacturers below can they order right now, and whether a different strength or form of Methylphenidate Hydrochloride Tablet, Extended Release is available. For alternatives, talk to your prescriber — see what to do if your medication is in shortage.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88) NDC 57664-606-88 |
Sun Pharmaceutical Industries, Inc. | Unavailable | Currently not marketed |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01) NDC 62037-725-01 |
Teva Pharmaceuticals USA, Inc. | Limited | Estimated recovery: September 2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10) NDC 13811-706-10 |
Trigen Laboratories, LLC | Limited | Allocation to current contracted customers |
| Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01) NDC 50458-585-01 |
Janssen Pharmaceuticals | Available | - |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37) NDC 62175-310-37 |
Lannett Company, Inc. | Available | - |
| Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10) NDC 68025-095-10 |
Vertical Pharmaceuticals, LLC | Available | - |
| Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30) NDC 68025-095-30 |
Vertical Pharmaceuticals, LLC | Available | - |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88) NDC 57664-607-88 |
Sun Pharmaceutical Industries, Inc. | Unavailable | Currently not marketed |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37) NDC 62175-311-37 |
Lannett Company, Inc. | Limited | Estimated recovery: November 2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10) NDC 13811-707-10 |
Trigen Laboratories, LLC | Limited | Allocation to current contracted customers |
| Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01) NDC 50458-588-01 |
Janssen Pharmaceuticals | Available | - |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01) NDC 62037-734-01 |
Teva Pharmaceuticals USA, Inc. | Available | - |
| Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30) NDC 68025-096-30 |
Vertical Pharmaceuticals, LLC | Available | - |
| Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10) NDC 68025-096-10 |
Vertical Pharmaceuticals, LLC | Available | - |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88) NDC 57664-608-88 |
Sun Pharmaceutical Industries, Inc. | Unavailable | Currently not marketed |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37) NDC 62175-312-37 |
Lannett Company, Inc. | Limited | Estimated recovery: November 2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01) NDC 62037-726-01 |
Teva Pharmaceuticals USA, Inc. | Limited | Estimated recovery: September 2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10) NDC 13811-708-10 |
Trigen Laboratories, LLC | Limited | Allocation to current contracted customers |
| Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01) NDC 50458-586-01 |
Janssen Pharmaceuticals | Available | - |
| Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30) NDC 68025-097-30 |
Vertical Pharmaceuticals, LLC | Available | - |
| Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10) NDC 68025-097-10 |
Vertical Pharmaceuticals, LLC | Available | - |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30) NDC 13811-711-30 |
Trigen Laboratories, LLC | Limited | Allocation to current contracted customers |
| Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30) NDC 68025-088-30 |
Vertical Pharmaceuticals, LLC | Available | - |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88) NDC 57664-609-88 |
Sun Pharmaceutical Industries, Inc. | Unavailable | Currently not marketed |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10) NDC 13811-709-10 |
Trigen Laboratories, LLC | Limited | Allocation to current contracted customers |
| Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01) NDC 50458-587-01 |
Janssen Pharmaceuticals | Available | - |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37) NDC 62175-313-37 |
Lannett Company, Inc. | Available | - |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01) NDC 62037-727-01 |
Teva Pharmaceuticals USA, Inc. | Available | - |
| Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30) NDC 68025-098-30 |
Vertical Pharmaceuticals, LLC | Available | - |
| Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10) NDC 68025-098-10 |
Vertical Pharmaceuticals, LLC | Available | - |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30) NDC 13811-700-30 |
Trigen Laboratories, LLC | Limited | Allocation to current contracted customers |
| Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30) NDC 68025-089-30 |
Vertical Pharmaceuticals, LLC | Available | - |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30) NDC 13811-710-30 |
Trigen Laboratories, LLC | Limited | Allocation to current contracted customers |
| Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30) NDC 68025-084-30 |
Vertical Pharmaceuticals, LLC | Available | - |
Related medications in shortage
Other Psychiatry medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
No changes recorded yet.
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Methylphenidate Hydrochloride Tablet, Extended Release (FDA data as of Sep 18, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Methylphenidate Hydrochloride Tablet, Extended Release. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Check your inbox - click the confirmation link to activate
alerts for Methylphenidate Hydrochloride Tablet, Extended Release.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/methylphenidate-hydrochloride-tablet-extended-release.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).